The mixed Phase 3 data (failed primary endpoint but strong subgroup signals) creates a high-risk binary scenario. Monitor for FDA feedback on the proposed LEVEL-2 enrichment strategy and any partnership or financing announcements. The stock could move significantly on regulatory clarity or capital raise news given the $82M market cap and ongoing trial costs.
Price Chart
Executive Summary
Tenax Therapeutics presented additional Phase 3 LEVEL trial data for TNX-103 (oral levosimendan) in PH-HFpEF at ESC 2026. The primary endpoint (6MWD) and key secondary endpoint (KCCQ-TSS) missed statistical significance in the overall population, but prespecified subgroup analyses showed a +26.3-meter improvement in 6MWD (p=0.0112), a 47% reduction in NT-proBNP (p<0.0001), and a -4.9 mmHg reduction in RVSP (p=0.009) in patients with baseline 6MWD below the trial median of 333 meters. The company plans to enrich the LEVEL-2 trial for this subgroup, but the mixed results and failed primary endpoint create significant uncertainty about the drug's path to approval, making this a high-risk binary event for a development-stage company with an $82M market cap and no approved products.
Key Facts
- Phase 3 LEVEL trial missed primary endpoint (6MWD) and key secondary endpoint (KCCQ-TSS) in overall population (n=241).
- Prespecified subgroup with baseline 6MWD <333m showed +26.3m improvement vs placebo (p=0.0112), 47% NT-proBNP reduction (p<0.0001), and -4.9 mmHg RVSP reduction (p=0.009).
- Company plans to enrich LEVEL-2 for patients with lower baseline walking distance based on these results.
- TNX-103 was safe and well-tolerated with no significant arrhythmias.
- No approved treatments exist for PH-HFpEF, representing a large unmet need.
Financial Impact
No financial data provided; company is pre-revenue development-stage with $82M market cap.
Risk Factors
- FDA may not accept enrichment strategy based on subgroup analysis, requiring a new Phase 3 trial.
- Cash runway and potential dilutive financing needs not disclosed; development-stage company with no revenue.
- Primary endpoint failure in overall population raises skepticism about drug's efficacy despite subgroup signals.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3352929 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | SC 13G/A | $1.36 $1.72 | ▲ +26.47% | ▲ +26.90% | $1.64 (+20.59%) |
Oct 13, 2026 14d ago | SC 13G/A | $1.60 $1.63 | ▲ +1.88% | ▲ +3.03% | $1.64 (+2.50%) |
Oct 9, 2026 17d ago | SC 13G/A | $1.83 $1.52 | ▼ −16.94% | ▼ −15.45% | $1.64 (−10.38%) |
Oct 8, 2026 18d ago | 8-K | $1.87 $1.36 | ▼ −27.27% | ▼ −25.30% | $1.64 (−12.30%) |
Sep 17, 2026 5w ago | Insider Cluster | $1.90 $1.81 | ▼ −4.74% | ▼ −6.01% | $1.64 (−13.68%) |
Sep 9, 2026 6w ago | 8-K | $2.13 $1.82 | ▼ −14.55% | ▼ −13.90% | $1.64 (−23.00%) |
Aug 29, 2026 8w ago | Press Release | $1.84 $2.05 | ▲ +11.20% | ▲ +11.34% | $1.64 (−10.87%) |
Aug 10, 2026 11w ago | 8-K | $1.38 $1.71 | ▲ +24.36% | ▲ +24.41% | $1.64 (+19.27%) |
Aug 10, 2026 11w ago | Press Release | $1.38 $1.71 | ▲ +24.36% | ▲ +24.41% | $1.64 (+19.27%) |
Jul 31, 2026 12w ago | 8-K | $13.70 $13.44 | ▼ −1.90% | ▼ −5.41% | $1.64 (−88.03%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers